<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Immunology and Molecular Pathology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0501ED42-8914-45AD-8BE1-941F808B3516"><gtr:id>0501ED42-8914-45AD-8BE1-941F808B3516</gtr:id><gtr:firstName>Joseph Frank</gtr:firstName><gtr:surname>Standing</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002305"><gtr:id>EF6C4976-9679-4624-88EA-1844524A90F1</gtr:id><gtr:title>Mathematical and Statistical Modelling of CCR5 Inhibitor Effects in Adults and Children with HIV-1 Infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1002305</gtr:grantReference><gtr:abstractText>This study will use mathematical models to find out how medicines for HIV act in children and adults. Measurements of blood concentrations of white cells, viral load and drugs levels in patients receiving different medicine combinations will be used. Mathematical models are descriptions of these measurements using a system of equations. The main outcome is to find a model that describes the measurements in a way that relates to biological processes. Investigating which parts of the model differ between patient groups and different treatment regimes will answer questions such as: What happens to white cell counts if different drug combinations or doses are used? Can we predict paediatric drug effects from adult data and expected biological differences? What happens to viral load and white cell count if doses are missed? By creating a model of the system including drug levels, viral load and white cell counts, a better understanding of how these relate to each other is gained. This understanding will make the development of new medicines more efficient, and help optimise the use of current medicines. What makes this study special is the mathematical modelling techniques proposed have not been widely applied to HIV infection.</gtr:abstractText><gtr:technicalSummary>CCR5 receptor inhibitors are a new class of antiretroviral that inhibit viral entry into host immune cells. This work aims to use mathematical/statistical modelling to understand the long-term effects of CCR5 inhibitors in adults and children. A major difference between the method proposed and a purely statistical approach is that ordinary differential equations will be applied to longitudinal data. This novel method allows fitting of mechanistic models to sparse, unbalanced observations, giving the potential to go beyond merely describing the data, to making predictions under varying hypothetical conditions. Exploration of developmental differences between adults and children, determining the place of CCR5 inhibitors in HIV-1 therapy, and mathematical investigation of non-adherence to antiretroviral medications are key objectives. 
 Longitudinal data on viral load and CD4 counts in 1934 HIV-1-infected adults treated with antiretroviral regimens including the CCR5 inhibitor maraviroc will be used in the first part, which aims to develop a mechanistic model describing the changes in CD4 count and viral load over 48 weeks of treatment. The studies available provide data on various drug combinations, along with data in patients with non-CCR5 tropic HIV-1 infection, which will be useful in investigating immune system effects in the absence of observed antiretroviral activity. Pharmacokinetic data will also be integrated into the model.The second part adds paediatric data from around 100 subjects to be analysed using the adult mechanistic model. Developmental differences in both immunology and drug effects will be investigated through covariate model building guided by prior knowledge of ontogeny. Using the mechanistic insights gained, optimal design of treatment strategies in both clinical HIV-1 treatment and antiretroviral study design will be possible. Using the data and model, the final study is an investigation on the impact of non-adherence on drug concentrations, CD4 count and viral load. Novel methods for identifying patterns of non-adherence and for appropriate handling of data suspected to arise from non-adherence will be developed, which will be used to detect and predict its impact on clinical effect. Scientific opportunities presented in this work include access to large clinical datasets, and the chance to employ sophisticated mathematical and statistical modelling techniques that have not been widely applied to this field. The medical opportunities lie in using mathematical models to investigate antiretroviral mechanisms. Simulation from model parameters will guide the design of future studies and provide treatment recommendations for clinical practice, in particular on the place of CCR5 inhibitors.</gtr:technicalSummary><gtr:fund><gtr:end>2015-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>435359</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Joined European Medicines Agency Modelling and Simulation Working Group</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>CEBCBD83-FDF8-4D5D-A4DB-4E7B48C069B6</gtr:id><gtr:impact>Membership of the European Medicines Agency (EMA) Modelling and Simulation Working Group (MSWG) is drawn from regulatory agencies and academic institutions across Europe. The MSWG was set up in 2013 in response to the increasingly complex nature of mathematical and statistical modelling information being submitted to regulatory agencies by pharmaceutical companies. We meet monthly to provide expert input to other EMA groups (mainly Scientific Advice Working Party, Paediatric Committee) on questions they have regarding modelling and simulation material submitted by pharmaceutical companies. The feedback is usually written but often MSWG members will also attend meetings directly with the pharmaceutical companies.</gtr:impact><gtr:outcomeId>546346d9652392.31014801</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>The model described in:
Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants.
Germovsek E, Kent A, Metsvaht T, Lutsar I, Klein N, Turner MA, Sharland M, Nielsen EI, Heath PT, Standing JF.
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4869-77. doi: 10.1128/AAC.00577-16. PMID: 27270281 

has been made available free in the following website: 
http://www.tdmx.eu/</gtr:description><gtr:id>36386B25-9DB5-48FE-982D-EFE04A63C0EF</gtr:id><gtr:impact>Clinicians in neonatal intensive care do not now need to take a separate blood sample for monitoring gentamicin levels, rather using the model and result from leftover blood from another test at any point in the dosing interval can be used to predict when it is safe to give the next dose.</gtr:impact><gtr:outcomeId>58bd7bce77a3d0.30265722</gtr:outcomeId><gtr:title>NeoGent Bayesian software</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://www.tdmx.eu/</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>32DEFD77-DA24-489C-B51A-8C22331B109E</gtr:id><gtr:title>Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.</gtr:title><gtr:parentPublicationTitle>Advanced drug delivery reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5449787deff20596003b011bf4953347"><gtr:id>5449787deff20596003b011bf4953347</gtr:id><gtr:otherNames>Barker CI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0169-409X</gtr:issn><gtr:outcomeId>pm_540e178e1780c5b26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3700868-90A3-4937-92A2-6C2A706C2E56</gtr:id><gtr:title>Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5449787deff20596003b011bf4953347"><gtr:id>5449787deff20596003b011bf4953347</gtr:id><gtr:otherNames>Barker CI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>pm_14299_29_22517604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>130AB8CA-72FD-4207-90D5-5B4C1EAA2A6C</gtr:id><gtr:title>Pharmacokinetics of doripenem during high volume hemodiafiltration in patients with septic shock.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7904b3c28dcb610b3b2d1a733a0883ef"><gtr:id>7904b3c28dcb610b3b2d1a733a0883ef</gtr:id><gtr:otherNames>Tamme K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-2700</gtr:issn><gtr:outcomeId>doi_55faa2aa2112d643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9842597C-A05A-4A18-8AF8-03E2491B523B</gtr:id><gtr:title>Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e5d80bacc04b8d7ba12ec91dc5a7521"><gtr:id>4e5d80bacc04b8d7ba12ec91dc5a7521</gtr:id><gtr:otherNames>Germovsek E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>585d6a15693c76.84381358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67F4C61C-EBB0-42AD-A0BD-BF058BEC1939</gtr:id><gtr:title>Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c55bff97465fc86ce9da667f9962f42"><gtr:id>2c55bff97465fc86ce9da667f9962f42</gtr:id><gtr:otherNames>Hennig S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>pm_14299_29_23420517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C8A0E97-025F-4747-AD13-90E2D6512C77</gtr:id><gtr:title>Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1532b31075e1bd5d72c407052e719c7c"><gtr:id>1532b31075e1bd5d72c407052e719c7c</gtr:id><gtr:otherNames>Lutsar I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_14299_29_21958494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>196253CB-0FE6-4F0A-8D23-6420C2C4150A</gtr:id><gtr:title>Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children.</gtr:title><gtr:parentPublicationTitle>Infectious disorders drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6b3fc02ca7e4d773c5264f7c53c5b9e"><gtr:id>d6b3fc02ca7e4d773c5264f7c53c5b9e</gtr:id><gtr:otherNames>Standing JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1871-5265</gtr:issn><gtr:outcomeId>pm_14299_29_23675922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E376DA99-522E-4DF9-A212-8B3180950E38</gtr:id><gtr:title>Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/526caea4417fdcda9bace85bbf10603e"><gtr:id>526caea4417fdcda9bace85bbf10603e</gtr:id><gtr:otherNames>De Cock PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>56d9af1f9433d8.46329417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>364B75F9-782B-4FE6-8D16-DD2A9D09A490</gtr:id><gtr:title>Mathematical modelling to restore circulating IGF-1 concentrations in children with Crohn's disease-induced growth failure: a pharmacokinetic study.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d4a7b956c2ceb51553182b440538b20"><gtr:id>0d4a7b956c2ceb51553182b440538b20</gtr:id><gtr:otherNames>Rao A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_14299_29_23793696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5EF6F6F-0413-4738-968E-776C54872D8A</gtr:id><gtr:title>Short versus long infusion of meropenem in very-low-birth-weight neonates.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7871110caa2e7beed1c6099266d8bc8"><gtr:id>a7871110caa2e7beed1c6099266d8bc8</gtr:id><gtr:otherNames>Padari H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_14299_29_22733063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70262D95-1379-4695-8469-D51A121E8A04</gtr:id><gtr:title>Liquid chromatography-tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children</gtr:title><gtr:parentPublicationTitle>Wellcome Open Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/947918cc633e44f0ffb368f70bb78b15"><gtr:id>947918cc633e44f0ffb368f70bb78b15</gtr:id><gtr:otherNames>Ongas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a2fd89a8b58a1.23487662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA27E2A1-1DFD-4CBF-862F-F56C8425DDA1</gtr:id><gtr:title>Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6b3fc02ca7e4d773c5264f7c53c5b9e"><gtr:id>d6b3fc02ca7e4d773c5264f7c53c5b9e</gtr:id><gtr:otherNames>Standing JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_14299_29_22564835</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002305</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>